Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss
Analysts Agreed The S1P Receptor Modulator Should Advance
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
You may also be interested in...
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.